Preclinical efforts, now followed by clinical studies, have been focusing on B cell malignancies, specifically the combinations of the B-lineage antigens CD19 and CD22 in ALL [70] and CD19 and CD20 in NHL [71,72]. Here, CD22 is linked to non-Hodgkin lymphoma.